Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Oncogene. 2020 Dec 1;40(4):806–820. doi: 10.1038/s41388-020-01569-5

Figure 2. CYSLTR2, GNAQ/11, and PLCβ act in a linear signaling cascade that activates MAP-kinase via PKC.

Figure 2

(A) The effect of YM-254890 on IP1 accumulation induced by different Gαq mutants. 293FT cells transfected with indicated cDNAs for 24 hours were treated with YM at indicated concentrations for 2h (20,000 cells per sample). Error bars represent the SEM.

(B) PKC and MAPK pathways are activated by mutations of GNAQ, GNA11, CYSLTR2, and PLCB4 and PKC activation is upstream of the MAP-kinase pathway. 293FT cells transfected with different Gαq variants were treated with DMSO (D), the Gαq inhibitor YM-254890 (YM) at 100nM, the PKC inhibitor LXS196 (LXS) at 1μM, or the MEK inhibitor Trametinib (TRA) at 100nM for 24 hours.